Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, by Drug Class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Nov 2020

Code : CMI1538

Pages :186

Formats :

Excel and PDF

Industry : Pharmaceutical

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs MarketSize and Trends

The global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs is estimated to be valued at US$ 984.6 million in 2020 and is expected to exhibit a CAGR of 4.4% over the forecast period (2020-2027).

Increasing product launches and approvals are expected to drive the market growth over the forecast period

Growing incidence of infections associated with Methicillin-resistant staphylococcus aureus (MRSA) pathogens is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant staphylococcus aureus (MRSA), which is expected to boost the Methicillin-resistant staphylococcus aureus (MRSA) drugs market growth. For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the U.S. market. The drug is available in a once-daily intravenous and oral antibiotic. It is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including gram-positive, gram-negative, atypicals, and other drug-resistant strains.

Furthermore, adoption of inorganic growth strategies such as merger, acquisition, collaborations by key players is one of the key factors responsible for growth of the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market For instance, in March 2019, Melinta Therapeutics entered into an exclusive license, supply, and distribution agreement with Hikma Pharmaceuticals. The deal include distribution rights of Melinta’s intravenous and oral formulations of antibiotic Baxdela (delafloxacin), across Middle East and North Africa markets.

Increasing number of pipeline products is expected to drive the market growth over the forecast period

Rising number of pipeline products for MRSA drugs is also a major factor that is expected to boost growth of the global Methicillin-resistant staphylococcus auresus (MRSA) drugs. For instance, in March 2017, Durata Therapeutics Inc. initiated phase 3 clinical trial study on dalbavancin to determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children caused by susceptible gram-positive organisms Methicillin-resistant strains of Staphylococcus aureus.